Eli Lilly’s “unusual ammo” to fend off generic competition

Eli Lilly, who are facing rather a large patent cliff, is employing what Reuters call "unusual ammo" to fend off generic competition. Lilly is currently embroiled in a patent battle with generic drug manufacturer Teva Pharmaceutical Industries, centred around Lilly's lung cancer drug Alimta. Last summer, the US Court of Appeals upheld the validity of the patent on Alimta's chemical …

Another Alzheimer’s drug candidate suffers setback

It's not been a good couple of years for Alzheimer's research. Recently, Baxter's Gammagard joined J&J and Pfizer's iv bapineuzumab and Eli Lilly's solanezumab in a list of late-stage failures. Now, Lilly has voluntarily stopped a phase II trial of another of its Alzheimer's disease drug candidates. This time, it was the company's beta secretase 1 (BACE-1) inhibitor, LY2886721, that …

“Crowd sourcing drug development”. Can it really lead to drug repositioning?

After the NCATS pilot program ‘Discovering New Therapeutic Uses for Existing Molecules' was launched in May, a lot has been discussed about its potential and the actual feasibility to reposition one or some of the 58 compounds contributed by the eight big pharma joining the project. Experts in the field of drug repurposing say that there's very little opportunity for …

How to develop innovative treatments for neglected diseases – presentation by Novartis

Lynne McGrath, Vice President and US DRA Head of Oncology at Novartis, presented at last year’s World Orphan Drug Congress USA on the drug Glivec, and how it was approved for not one but four orphan indications. Though not drug repositioning in the strictest sense, could Novartis’s expertise in expanding indications for one drug be a way to streamline several …